Vaccine

Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)

Licensed antigens are shared across major subsets of NSCLC and have confirmed presence on the surface of tumor cells, homogeneous…

1 year ago

Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates

BOTHELL, Wash., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides an update…

1 year ago

Kiniksa Pharmaceuticals Provides Corporate Update

– ARCALYST® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) – – ARCALYST 2024 net product…

1 year ago

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer’s and Parkinson diseases

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD…

1 year ago

Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference

CAPE CANAVERAL, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of…

1 year ago

Rapid Micro Biosystems to Present at 42nd Annual J.P. Morgan Healthcare Conference

LOWELL, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences…

1 year ago

Arrigo Medical Devices to Showcase Innovations at the 77th PostGraduate Assembly in Anesthesiology in New York

Arrigo Medical Devices announces its expansion into airway management devices and drugs, showcasing its latest innovations at the 77th PostGraduate…

1 year ago

Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference

JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology…

1 year ago

TechImmune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- TechImmune, LLC., a biotechnology company developing a broad-spectrum, next generation coronavirus…

1 year ago

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

PRINCETON, NJ / ACCESSWIRE / December 21, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic…

1 year ago